(Boursier.com) — OSE Immunotherapeutics SA announces that the scientific advances from its research programs have been selected for presentation at upcoming European and American congresses: at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20-23), at the 38th Annual Congress of SITC (Society for Immunotherapy of Cancer) in San Diego, CA, USA (November 1-5) and at the 15th PEGS Europe (Protein & Antibody Engineering Summit) in Lisbon, Portugal (November 14-16).
Communications will focus on the latest advances in the company’s immuno-oncology research programs: CLEC-1 (new myeloid immune checkpoint), CYTOMASK (new innovative cytokine unmasking technology), BiCKI-IL-7 (bifunctional targeting PD-1 and IL-7) and Tedopi (epitope-based T cell activation therapeutic cancer vaccine).
Nicolas Poirier, Managing Director of OSE Immunotherapeutics, comments: “OSE will present 9 communications at the next leading international scientific conferences. We are proud of the results obtained by our teams of researchers on the advancement of our innovative programs. We are involved in the progression of these programs towards the clinical development stages thanks to strategic collaborations with academic partners and/or pharmaceutical laboratories, in order to ultimately be able to bring first-in-class immunotherapies to patients with a strong medical need.”
©2023 Boursier.com